“showed a trend”

Significant differences were observed between the two subtypes in terms of sex ( p = 0.003), PSQI ( p = 0.0004), SAS ( p < 0.0001), and SDS ( p < 0.0001), whereas age showed a trend toward difference but did not reach statistical significance ( p = 0.064) ( Table 2 ).

longum APC1472 showed a trend toward restoring DOPAC synthesis ( t 18.3 = −1.30, q = 0.208, d = 0.53) (Supplementary Fig.

33 – 36 In our study, non-carriers of the CYP2C19 LoF allele showed a trend of a higher bleeding risk, but the interaction did not show statistical significance when interaction was investigated separately per trial ( Supplementary Figure IV ).

This aligns with our findings: in early-stage patients, none received concurrent chemotherapy, and earlier RT showed a trend toward better outcomes; whereas in locally advanced patients, the significant DFS difference was observed only in those who received concurrent chemotherapy.

Firstly, participants showed a trend of improvement in pain, functionality, and quality of life throughout the study duration; however, further studies are needed to confirm the carry-over effects of PEMF therapy, especially considering the attrition caused by loss to follow-up in the long-term assessment.

TXL treatment showed a trend toward reducing composite end events.

Although the difference was not statistically significant, Osteogrow-C with TCP or BCP, containing a high proportion of TCP (TCP/HA 80/20), showed a trend toward superiority over Osteogrow-C containing HA or BCP with a high proportion of HA (TCP/HA 40/60) (Fig. 7 E).

Analysis of the abdominal and lumbar paraspinal muscles in the same field of view (FOV) as the diaphragmatic crura also showed a trend toward lower mean T1 values in LOPD patients (abdominal muscles 858.06 ± 405.05 ms; paraspinal muscles 851.02 ± 397.83 ms) when compared to controls (abdominal muscles 1185.16 ± 172.24 ms; paraspinal muscles 1157.85 ± 39.91 ms) (LOPD vs. controls: abdominal muscles, p = 0.28 and paraspinal muscles, p = 0.05) (Figure 5 ).

In this cohort, DLRT showed a trend towards better survival than CLSLRT in RLD patient undergoing lung retransplantation for BOS, although this did not reach statistical significance.

Significant heterogeneity was observed (I 2 = 47.9%), driven by a divergence between observational studies, which favored TTM (RR 0.90; 95% CI 0.63-1.27), and RCTs, which showed a trend toward harm or neutrality (RR 1.05; 95% CI 0.86-1.28).

Of note, several tRNAs showed a trend toward higher aminoacylation percentages ( Figs. 2 A , S1 F ).

S1e), their absolute numbers showed a trend toward increase, despite not reaching statistical significance.

Co-localization of BNIP3, BNIP3L and phospho-BNIP3L with mitochondria basally showed a trend toward being reduced, however, due to large variability between both controls and patients this did not reach statistical significance ( Figure 5 and Supplementary Figure 6 ).

In all patients, the myocardial markers (e.g., CK, r = 0.625; CKMB, r = 0.476; AST, r = 0.401 and LDH, r = 0.528; all P < 0.05) and certain inflammatory markers (e.g., WBC, r = 0.557; NEU, r = 0.270; NLR, r = 0.349; and MON, r = 0.407; all P < 0.05) exhibited an positive correlation with the eSCORE-CARD values, while other variables (e.g., TyG, r = − 0.290; basophil count [BAS], r = − 0.309; and high density lipoprotein cholesterol [HDL-C], r = − 0.246; all P < 0.05) showed a trend of negative correlation (Fig. 5 E).

Closeness in the family showed a trend toward improvement, suggesting a potential impact that warrants further investigation in larger samples.

40 , 63 , 64 ARX PAE COs had significantly fewer PAX6 + cells than controls ( p = 0.0085, d = 0.955; Figures 3F - 3H ) and showed a trend toward decreased HES1 expression ( Figures S19A - S19D ), while HES5 expression trended upward ( Figures S19A - S19D ).

Moreover, in both treatment groups, patients with the following symptoms at baseline as swelling, tenderness, crepitus, inflammation, pain in motion, effusion and positive heel to buttock showed a trend toward resolution over the course of the study.

In terms of the age of patients with onset of disease, both the sIAD group and the non-IAD IS group showed a trend toward younger age relative to the ICH group, yet the sIAD group did not show heterogeneity in ORs compared to the non-IAD IS group in terms of age, as has been found in previous large-scale studies [ 20 , 25 ], which may be related to the small size of our sample.

The fit indices for the five-factor model had already markedly decreased (CFI = 0.622, TLI = 0.776, RMSEA = 0.116), and the more simplified models showed a trend of further deterioration, with the single-factor model yielding the worst fit (CFI = 0.453, TLI = 0.419).

At the end of the experiment, compared with the ND group, serum cholesterol showed a trend toward higher levels in AD; compared with control, HFD and HFD+AD showed a significant increase in serum cholesterol levels.

Conversely, the average_degree in dense habitats showed a trend of increasing risk of disease progression.

Patients in cohort 1 with poor prognostic factors (older age, high GGG, low Hb, and elevated LDH) showed a trend towards earlier decline in OS than those in cohort 2B, which may indicate that caution is required when cohort 1 treatment is selected for patients with poor prognostic factors.

Stone-related pyonephrosis demonstrated significantly higher salvage rates, whereas xanthogranulomatous pyelonephritis, malignancy, and tubercular kidneys, conditions associated with extensive parenchymal destruction, showed a trend toward non-salvageability.

However, in the ABF21013 treatment groups (UVB+ABF21013_L, UVB+ABF21013_H), the increase in HAS1 and HAS2 mRNA expression showed a trend but was not statistically significant (compared to the UVB-only treatment group).

Multiple births (p = 0.081) showed a trend toward association with lower follow-up adherence.